Skip to main content
SpringerLink
Log in

Increased support for β-blocker use in patients with heart failure

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J 1997 May; 18: 736–53

    Article  Google Scholar 

  2. Consensus recommendations for the treatment of patients with heart failure. Am J Cardiol 1999 Jan 21; 83 Suppl. 2A: 1A–38A

    Google Scholar 

  3. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441–6

    Article  PubMed  CAS  Google Scholar 

  4. White M, Rouleau J-L, Pericak D, et al. Effects of metoprolol-CR in patients with ischaemic and dilated cardiomyopathy: the RESOLVD pilot study (phase II) [abstract]. Eur Heart J 1998; 19 (Suppl.): 308

    Article  Google Scholar 

  5. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF). Lancet 1999 Jun 12; 353: 2001–7

    Google Scholar 

  6. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765–73

    Article  Google Scholar 

  7. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999 Jan 2; 353: 9–13

    Article  Google Scholar 

  8. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94: 2800–6

    Article  PubMed  CAS  Google Scholar 

  9. Australian/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375–80

    Article  Google Scholar 

  10. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of Carvedilol in patients with moderate to severe heart failure. Circulation 1996; 94: 2793–9

    Article  PubMed  CAS  Google Scholar 

  11. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807–16

    Article  PubMed  CAS  Google Scholar 

  12. Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. J Card Failure 1997; 3: 173–9

    Article  CAS  Google Scholar 

  13. Cleland JGF, McGowan J, Clark A. The evidence for beta blockers in heart failure: equals or surpasses that for angiotensin converting enzyme inhibitors. BMJ 1999 Mar 27; 318: 824

    Article  PubMed  CAS  Google Scholar 

  14. Packer M, Bristow MR, Cohn JN, et al. The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N Eng J Med 1996 May 23; 334: 1349–55

    Article  CAS  Google Scholar 

  15. Hjalmarson Å, Kneider M, Waagstein F. The role of β-blockers in left ventricular dysfunction and heart failure. Drugs 1997 Oct; 54(4): 501–10

    Article  PubMed  CAS  Google Scholar 

  16. New consensus report urges four-drug regimen for stable heart failure patients. Formulary 1999 Mar; 34: 202

    Google Scholar 

  17. Carvedilol more than an antihypertensive: new data show efficacy in CHF and MI. Drug Ther Perspect 1997 Nov 10; 10(10): 1–5

    Google Scholar 

  18. Lindsay J, Freemantie N, Nazareth I. β-blockers in heart failure. Lancet 1999 Mar 20; 353: 1011

    Article  PubMed  CAS  Google Scholar 

  19. Avezum Á, Tsuyuki RT, Pogue J, et al. Beta-blocker therapy for congestive heart failure: a systematic overview and critical appraisal of the published trials. Can J Cardiol 1998 Aug; 14(8): 1045–53

    PubMed  CAS  Google Scholar 

  20. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807–16

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Increased support for β-blocker use in patients with heart failure. Drugs Ther. Perspect 14, 9–11 (1999). https://doi.org/10.2165/00042310-199914030-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199914030-00003

Keywords

Search

Navigation